Pharmacists Must Prepare for a New Role in Psychedelic Therapies
As psychedelic therapies continue to gain ground in the popular zeitgeist and edge closer to clinical use, pharmacists need to develop new competencies beyond customary medication management. In an exclusive interview with Pharmacy Times, Sa’ed al-Olimat, PharmD, thinks the FDA’s recent decision on 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy highlights why pharmacists must be educators in this rapidly evolving therapeutic space.
Question: Since your last conversation with us, what new developments in psychedelic research do you think pharmacists should be aware of or paying attention to?
On the Al-Olimat, ParmD: One of the biggest developments since our last conversation is the FDA’s formal issuance of the Complete Response Letter regarding MDMA-assisted therapy. While the advisory committee vote gave some early indication of the challenges ahead, the CRL made it official that MDMA will not yet move forward to approval. The rationale provided by the FDA has sparked an crucial and ongoing conversation across the psychedelic research and clinical communities.
What pharmacists should be paying attention to now is less about the basic pharmacology, which remains promising and should still be a priority learning objective, but more about how psychedelic clinical trials are being evaluated. There is increasing tension between the demand for rigorous methodology and the reality that traditional double-blind designs are uniquely arduous in psychedelic research. With substances like MDMA and psilocybin, participants can often tell whether they received the active drug. This complicates blinding and raises questions about how trial outcomes should be interpreted.
This has implications far beyond MDMA alone.It affects how future psychedelic trials will be designed, regulated, and ultimately approved. pharmacists will need to stay informed not only on drug mechanisms and interactions, but also on evolving regulatory expectations and ethical considerations. We are entering a phase where pharmacists must be part pharmacologist, part educator, and part advocate.
Q: What is your response to the FDA’s Complete Response Letter and its impact on the future of MDMA-assisted therapy?
On the Al-Olimat, ParmD: The CRL was disappointing, but it should not be viewed as the end of the road. It reflects the FDA’s cautious stance toward approving a fundamentally new treatment model, especially one involving subjective experiences and psychotherapy.
[Image of Psilocybe cubensis Argentina]
Summary of the Provided Text:
This text discusses the recent FDA rejection of MDMA-assisted therapy for PTSD,the mechanisms of action of psychedelics,and the competencies pharmacists will need as these therapies become more prevalent. Here’s a breakdown:
1. FDA Rejection of MDMA Therapy:
* The FDA rejected MAPS’ application for MDMA-assisted therapy for PTSD, despite prior agreement on the trial design through a Special Protocol Assessment.
* This is seen as a setback and reflects the FDA’s caution regarding novel treatment models involving subjective experiences and psychotherapy.
* The rejection raises concerns about regulatory consistency and predictability.
* However, the FDA’s concerns about bias and safety are valid, and the field may need to refine methodologies (e.g., better placebos, crossover designs, objective measures) to meet stricter standards.
2. Psychedelic Mechanisms of Action (Dr.Al-Olimat):
* Classic psychedelics (psilocybin, LSD, DMT): Primarily act as agonists at the 5-HT2A receptor, disrupting brain network connectivity (especially the default mode network) and increasing neuroplasticity, emotional openness, and cognitive versatility.
* MDMA: Primarily a serotonin-releasing agent,also increasing oxytocin and other neurochemicals related to trust and emotional processing.
* Key misconception: Psychedelics are not a “magic pill.” Therapeutic benefit comes from the combination of the substance with structured psychological support (preparation, monitoring, integration).
* The experience can be challenging and requires a strong support system to avoid being overwhelmed or destabilized. Integration is crucial for lasting change.
* Psychedelic-assisted therapy is a collaborative process, not a passive pharmaceutical intervention.
3. Pharmacist Competencies (Dr. Al-Olimat):
* Pharmacological Knowledge: Understanding pharmacodynamics, pharmacokinetics, and drug-drug interactions of psychedelic compounds.
* Patient Counseling & Harm Reduction: Skills to navigate patient expectations, understand risks, and provide non-judgmental support.
* Interdisciplinary Collaboration: Working with other healthcare professionals.
* Potential Role: Pharmacists could play a key role in supporting patients throughout the entire process – preparation, dose-day, and integration. Some pharmacists are already receiving specialized training (like the MAPS 100-hour MDMA Therapy Training Program).
* Staying Informed: Continuous learning is essential.
In essence, the text highlights both the challenges and the potential of psychedelic-assisted therapies, emphasizing the need for rigorous research, refined methodologies, and a well-trained healthcare workforce (including pharmacists) to ensure safe and effective implementation.
Related reading